openPR Logo
Press release

GervanoRA Announced the Release of Opportunity Assessment Report Titled “Metachromatic Leukodystrophy Drugs – Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2018”

04-23-2019 01:15 PM CET | Health & Medicine

Press release from: GervanoRA Data Services

GervanoRA Announced the Release of Opportunity Assessment

GervanoRA Data Services (GDS), a premier provider of market research analysis and services based in Goa, India has announced the release of their latest report on Metachromatic Leukodystrophy Pipeline Drugs – Opportunity Assessments, Epidemiology Forecast, Market Dynamics, and Pipeline Analysis H2 2018.

GervanoRA’s pipeline analysis and opportunity assessment report “Metachromatic Leukodystrophy: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis, H2 2018” analyzed and assessed Metachromatic Leukodystrophy pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Metachromatic Leukodystrophy industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on
• Unmet needs and Opportunities
• Epidemiology and Epidemiology forecast 2019 – 2025
• Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
• Patent Analysis of Pipeline Molecules
• Pipeline Analysis and Estimated Pipeline Drug Approval Time lines
• Clinical Trials Summary
• Current and Future Competitive Landscape
• Key Company Profiles with SWOT Analysis
• Emerging Company Profiles with Opportunity Assessments
• Pipeline Drug Descriptions along with Development milestones (Past and Future)
• University Pipeline Molecules & In-Licensing/Out Licensing Opportunities

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. METHODOLOGY
1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
1.4. ABOUT US: GERVANORA DATA SERVICES
2. EXECUTIVE SUMMARY
2.1. REPORT MAJOR FINDINGS
2.2. KEY EVENTS IN METACHROMATIC LEUKODYSTROPHY COMPETITIVE SPACE
3. DISEASE OVERVIEW
3.1. DISEASE DEFINITION & SYMPTOMS
3.1.1. CLINICAL MANIFESTATIONS
3.1.2. PATHOGENESIS
3.2. DISEASE CAUSE AND CLASSIFICATION
3.3. DISEASE DIAGNOSIS
3.4. TREATMENT ALGORITHM AND GUIDELINES
3.5. EPIDEMIOLOGY AND DISEASE BURDEN
3.6. EPIDEMIOLOGY FORECAST
3.6.1. FORECAST METHODOLOGY AND ASSUMPTION
3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST
4. MARKET DYNAMICS
4.1. GOVERNMENT REGULATORY DYNAMICS AND IMPACT
4.2. PRICING AND REIMBURSEMENT
4.3. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
4.4. NEW DRUG APPROVALS (US FDA) SINCE 2010
4.5. NEW DRUG APPROVALS (EX-US) SINCE 2010
4.6. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)
5. PIPELINE ANALYSIS
5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
5.1.1. METACHROMATIC LEUKODYSTROPHY PHASE 3 MOLECULES
5.1.2. METACHROMATIC LEUKODYSTROPHY PHASE 2 MOLECULES
5.1.3. METACHROMATIC LEUKODYSTROPHY PHASE 1 MOLECULES
5.1.4. METACHROMATIC LEUKODYSTROPHY PRECLINICAL MOLECULES
5.1.5. METACHROMATIC LEUKODYSTROPHY EARLY R&D MOLECULES
5.1.6. METACHROMATIC LEUKODYSTROPHY INACTIVE AND DISCONTINUED MOLECULES
5.2. PIPELINE ANALYSIS BY GEOGRAPHY
5.2.1. UNMET NEEDS AND OPPORTUNITIES
5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
5.3.1. UNMET NEEDS AND OPPORTUNITIES
5.4. PIPELINE ANALYSIS BY DRUG CLASS
5.4.1. UNMET NEEDS AND OPPORTUNITIES
5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
5.5.1. UNMET NEEDS AND OPPORTUNITIES
5.6. PIPELINE MOLECULES BY UNIVERSITIES AND INSTITUTES
6 ESTIMATED APPROVAL TIMELINE
6.1.1. METHODOLOGY
6.1.2. ESTIMATED APPROVAL TIME LINES US & EX-US
7. METACHROMATIC LEUKODYSTROPHY CLINICAL TRIALS SUMMARY
7.1. METACHROMATIC LEUKODYSTROPHY PIPELINE ANALYSIS BY CLINICAL TRIALS RESULTS
7.1.1. KEY PHASE 3 RESULTS
7.1.2. KEY PHASE 2 RESULTS
7.2. ONGOING CLINICAL TRIALS SUMMARY
7.2.1 KEY PHASE 3 ONGOING CLINICAL TRIALS SUMMARY
7.2.2 KEY PHASE 2 ONGOING CLINICAL TRIALS SUMMARY
7.2.3. KEY PHASE 1 ONGOING CLINICAL TRIALS SUMMARY
7.3. PLANNED CLINICAL TRIALS SUMMARY
7.4. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY
7.4.1. RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS SUMMARY
7.4.2. RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS SUMMARY
7.4.3. RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS SUMMARY
8. CURRENT AND FUTURE COMPETITIVE LANDSCAPE
8.1. COMPANIES
8.1.1. ESTABLISHED COMPANY PROFILES WITH SWOT ANALYSIS
8.1.2. TOP 20 EMERGING COMPANIES IN THE METACHROMATIC LEUKODYSTROPHY AREA
8.3. UNIVERSITIES AND INSTITUTES – LICENSING OPPORTUNITIES
9. ABBREVIATIONS

LIST OF TABLES:

TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
TABLE 02: DISEASE EPIDEMIOLOGY (2017), FORECAST (2018-2025) IN MILLIONS
TABLE 03: MAJOR COLLABORATIVE AGREEMENTS IN THE METACHROMATIC LEUKODYSTROPHY AREA
TABLE 04: MAJOR LICENSING AGREEMENTS IN THE METACHROMATIC LEUKODYSTROPHY AREA
TABLE 05: MAJOR MERGERS AND ACQUISITIONS IN THE METACHROMATIC LEUKODYSTROPHY AREA
TABLE 06: MAJOR ALLIANCE AGREEMENTS IN THE METACHROMATIC LEUKODYSTROPHY AREA
TABLE 07: MAJOR FINANCING DEALS IN THE METACHROMATIC LEUKODYSTROPHY AREA
TABLE 08: MAJOR DEALS IN THE METACHROMATIC LEUKODYSTROPHY AREA RANKED BY DEAL AMOUNT
TABLE 09: US FDA APPROVED DRUGS SINCE 2010
TABLE 10: EX-US APPROVED DRUGS SINCE 2010
TABLE 11: PHASE 3 MOLECULES IN THE METACHROMATIC LEUKODYSTROPHY DRUG PIPELINE
TABLE 12: PHASE 2 MOLECULES IN THE METACHROMATIC LEUKODYSTROPHY DRUG PIPELINE
TABLE 13: PHASE 1 MOLECULES IN THE METACHROMATIC LEUKODYSTROPHY DRUG PIPELINE
TABLE 14: PRECLINICAL MOLECULES IN THE METACHROMATIC LEUKODYSTROPHY DRUG PIPELINE
TABLE 15: EARLY R&D MOLECULES IN THE METACHROMATIC LEUKODYSTROPHY DRUG PIPELINE
TABLE 16: INACTIVE AND DISCONTINUED MOLECULES IN THE METACHROMATIC LEUKODYSTROPHY DRUG PIPELINE
TABLE 17: METACHROMATIC LEUKODYSTROPHY PIPELINE MOLECULES BY ROUTE OF ADMINISTRATION
TABLE 18: METACHROMATIC LEUKODYSTROPHY PIPELINE MOLECULES OVERVIEW BY DRUG CLASS
TABLE 19: METACHROMATIC LEUKODYSTROPHY PIPELINE MOLECULES BY UNIVERSITIES
TABLE 20: METACHROMATIC LEUKODYSTROPHY PIPELINE MOLECULES BY INSTITUTES
TABLE 21: ESTIMATED APPROVAL Time lines OF PIPELINE MOLECULES
TABLE 22: KEY PHASE 3 ONGOING CLINICAL TRIALS
TABLE 23: KEY PHASE 2 ONGOING CLINICAL TRIALS
TABLE 24: KEY PHASE 1 ONGOING CLINICAL TRIALS
TABLE 25: PLANNED CLINICAL TRIALS FOR THE METACHROMATIC LEUKODYSTROPHY AREA
TABLE 26: RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS
TABLE 27: RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS
TABLE 28: RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS
TABLE 29: ESTABLISHED COMPANIES SCENARIO
TABLE 30: LIST OF EMERGING COMPANIES IN THE METACHROMATIC LEUKODYSTROPHY AREA
TABLE 31: COMPETITIVE OPPORTUNITIES, UNIVERSITIES
TABLE 32: COMPETITIVE OPPORTUNITIES, INSTITUTES
(Above mentioned tables are a few among the total 88 tables in the report)

LIST OF FIGURES:

FIGURE 01: KEY PIPELINE EVENTS, 2019-2029
FIGURE 02: METACHROMATIC LEUKODYSTROPHY EPIDEMIOLOGY (2017), FORECAST (2018-2025) IN MILLIONS
FIGURE 03: OVERALL DEALS ACTIVITY IN THE METACHROMATIC LEUKODYSTROPHY AREA
FIGURE 04: OVERALL DEAL FINANCING ACTIVITY V/S DEAL TYPE
FIGURE 05: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE
FIGURE 06: METACHROMATIC LEUKODYSTROPHY DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT
FIGURE 07: METACHROMATIC LEUKODYSTROPHY DRUG PIPELINE ANALYSIS BY GEOGRAPHY
FIGURE 08: METACHROMATIC LEUKODYSTROPHY DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT V/S GEOGRAPHIES
FIGURE 09: METACHROMATIC LEUKODYSTROPHY DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 10: METACHROMATIC LEUKODYSTROPHY DRUG PIPELINE ANALYSIS BY DRUG CLASS
FIGURE 11: METACHROMATIC LEUKODYSTROPHY PIPELINE MOLECULES DEVELOPED BY UNIVERSITIES AND INSTITUTES
FIGURE 12: ONGOING CLINICAL TRIALS SPLIT-UP BY HSD
FIGURE 13: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY HSD
FIGURE 14: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY MAJOR COMPANIES
FIGURE 15: COMPANY FINANCIAL INFORMATION
FIGURE 16: COMPANY SWOT ANALYSIS
(Above mentioned figures are a few among the total 49 figures in the report)

This report is available on promotional basis.

To view sample report: www.gervanora.com/request-for-sample-report/

Why Choose GervanoRA??

GervanoRA is working dedicatedly for healthcare (Pharma & Medical Device) domain to empower our client’s business by assisting them in decision making with our wealthiness of database, expertise in analytics, and domain experts.

Vast & Tailor-made Database: GervanoRA utilizes its in-built rich database of pharmaceutical sector and Medical device sector to help our clients with their bespoke requirements. We have databases of Pharma Pipeline Drugs, Pharma News, Pharma Deals and Pipeline Medical Devices, Medical Device News and Medical Device Deal.

Coverage: We cover almost all major countries on the globe by providing Pharma & Medical device pipeline insights along with epidemiology, epidemiology forecast, Patent analysis, Insights on clinical trials and emerging opportunities. Using our database analytics, we are cracking the future numbers to assess market opportunities in healthcare domain.

Resources to meet the Goals: We have great number of experts, Analysts, Senior Researchers and Researchers to take care of our dynamic day to day process, like building database, updating the database, optimizing primary inputs, using internal tools analytics, Conducting KOL Interviews and Gathering field intelligence through paid surveys in all healthcare markets.

About GervanoRA:

GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports and consulting services, based in Goa, India. GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.

At GervanoRA Data Services, we are playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations (KOLs) to garner valuable key insights.

To assist our global clients to attain their segment and sub segment specific goals, we are enlightening them on domain specific live updates through our GervanoRA 360 Degree PharmMedTech Monthly Bulletin (Monthly Report) which serve our clients with bespoke requirements without missing any live update for the particular month, as we know how valuable it is to be stayed updated with day to day dynamic industry sectors.

GervanoRA Data Services LLP
Goa IT Innovation Centre,
Goa Chamber of Commerce and Industry Bldg, 2nd Floor, S-2 Block,
Opp: Hyundai Showroom, Verna, South Goa,
Goa INDIA 403722
Email: sales@gervanora.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release GervanoRA Announced the Release of Opportunity Assessment Report Titled “Metachromatic Leukodystrophy Drugs – Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2018” here

News-ID: 1711959 • Views: 176

More Releases from GervanoRA Data Services

GervanoRA Announced the Release of Market Dynamics and Opportunity Assessment Re …
GervanoRA Data Services (GDS), a premier provider of market research analysis and services based in Goa, India has announced the release of their latest report on Hemophilia A - Opportunity Assessments, Epidemiology, Market Dynamics and Pipeline Analysis H2 2019 Report. GervanoRA’s pipeline analysis and opportunity assessment report “Hemophilia A: Opportunity Assessments, Epidemiology, Market Dynamics and Pipeline Analysis, H2 2019” analyzed and assessed Hemophilia A pipeline molecules for the opportunities in the
GervanoRA Announced the Release of Market Dynamics and Opportunity Assessment Re …
GervanoRA Data Services (GDS), a premier provider of market research analysis and services based in Goa, India has announced the release of their latest report on Schizophrenia - Opportunity Assessments, Epidemiology, Market Dynamics and Pipeline Analysis H2 2019 Report. GervanoRA’s pipeline analysis and opportunity assessment report “Schizophrenia: Opportunity Assessments, Epidemiology, Market Dynamics and Pipeline Analysis, H2 2019” analyzed and assessed Schizophrenia pipeline molecules for the opportunities in the competitive space by
GervanoRA Announced the Release of Market Dynamics and Opportunity Assessment Re …
GervanoRA Data Services (GDS), a premier provider of market research analysis and services based in Goa, India has announced the release of their latest report on Beta-Thalassemia Pipeline Drugs - Pipeline Analysis, Opportunity Assessments, Epidemiology Forecast, Market Dynamics, H2 2019 . GervanoRA’s pipeline analysis and opportunity assessment report “Beta-Thalassemia: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis, H2 2019” analyzed and assessed Beta-Thalassemia pipeline molecules for the opportunities in the
GervanoRA Announced the Release of Opportunity Assessment Report Titled “Aggre …
GervanoRA Data Services (GDS), a premier provider of market research analysis and services based in Goa, India has announced the release of their latest report on Aggressive Large B-cell Lymphoma Pipeline Drugs – Opportunity Assessments, Epidemiology Forecast, Market Dynamics, and Pipeline Analysis H2 2018. GervanoRA’s pipeline analysis and opportunity assessment report “Aggressive Large B-cell Lymphoma: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis, H2 2018” analyzed and assessed Aggressive Large

All 5 Releases


More Releases for METACHROMATIC

Gene Therapy Therapeutics-Pipeline Analysis 2018, Clinical Trials & Results | No …
Gene therapy is a technique that involves treatment or prevention of a disease by using genes. Several methodologies are being used in the gene therapy that involve replacing the mutated gene, inactivating or silencing the mutated gene, and introducing a new gene into the body. Download the sample report at: https://www.pharmaproff.com/request-sample/1184 This results in the formation of beneficial protein. A gene cannot be directly delivered into the human body, because of
Metabolic Disorders Therapeutics Market to Perceive Substantial Growth During 20 …
Metabolic disorders usually occur due to disruption of the normal processes of the body. These disorders can be hereditary or acquired and the symptoms differ from person to person. Some metabolic disorders cause mild symptoms that can be managed with slight medication and lifestyle changes, whereas few can cause life-threatening symptoms, such as breathing problems, seizure, and organ failure. The treatment for inherited metabolic disorders requires long-term nutritional supplementation and
Gene Therapy for Rare Disease Market Poised to Garner Maximum Revenues With Majo …
The global gene therapy for rare disease market size was valued at US$ 16.3 million in 2017, and is expected to witness a robust CAGR of 35.0% over the forecast period (2018–2026). In recent past, key players in the market have gained regulatory approvals and have launched their therapies in the market. Frequent approvals of novel gene therapies and their launches in the developed regions are expected to significantly drive gene
Metabolic Disorders Therapeutics Market 2017-2023 : Top Key Players are AbbVie, …
Metabolic disorders usually occur due to disruption of the normal processes of the body. These disorders can be hereditary or acquired and the symptoms differ from person to person. Some metabolic disorders cause mild symptoms that can be managed with slight medication and lifestyle changes, whereas few can cause life-threatening symptoms, such as breathing problems, seizure, and organ failure. The treatment for inherited metabolic disorders requires long-term nutritional supplementation and
Metachromatic Leukodystrophy Pipeline Therapeutics Review 2018
Metachromatic leukodystrophy (MLD) is an inherited disease that causes fat accumulation in cells. The disease affects the nervous system which produces myelin sheath for insulation and protection of nerves. The fatty deposition, called sulfatides in nerve cells causes the destruction of white matter, which is formed by myelin sheath. It further deteriorates the cognitive functioning of nerves such as an ability to walk, loss of sensation (also known as peripheral
Metachromatic Leukodystrophy Pharmaceutical and Healthcare Analysis Information
Pune, India, 18th December 2017: WiseGuyReports announced addition of new report, titled “Metachromatic Leukodystrophy (MLD) - Pipeline Review, H2 2017”. Summary Metachromatic leukodystrophy is an inherited disorder characterized by the accumulation of fats called sulfatides in cells. Symptoms include vision problems leading to blindness, personality changes, and motor disturbances such as clumsiness, muscle weakness (hypotonia), rigidity, inability to coordinate movement (ataxia), and/or muscle spasms especially of the neck, spine, arms, and legs.